Filtered By:
Procedure: Bone Graft
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 103 results found since Jan 2013.
Stroke-Related Hospitalization and Mortality After a Kidney Allograft: A Population-Cohort Study.
CONCLUSIONS: Fatal and nonfatal stroke-related events are common among kidney allograft recipients. Further research is warranted to allow better risk stratification and facilitate clinical trials for risk attenuation of stroke after a kidney transplant.
PMID: 26862824 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 1, 2016 Category: Transplant Surgery Authors: Ferro CJ, Karim A, Farrugia D, Bagnall D, Begaj I, Ray D, Sharif A Tags: Exp Clin Transplant Source Type: research
Stem cell transplantation for ischemic stroke.
CONCLUSIONS: Overall, in participants with ischemic stroke, stem cell transplantation was associated with a reduced neurological impairment, but not with a better functional outcome. No obvious safety concerns were raised. However, these conclusions came mostly from small RCTs with high risk of bias, and the certainty of the evidence ranged from low to very low. More well-designed trials are needed.
PMID: 31055832 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 4, 2019 Category: General Medicine Authors: Boncoraglio GB, Ranieri M, Bersano A, Parati EA, Del Giovane C Tags: Cochrane Database Syst Rev Source Type: research
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Abstract
Stroke is a major public health problem leading to high rates of death and disability worldwide, but no effective pharmacological therapy is currently available except for the use of PLAT (plasminogen activator, tissue). Here we show that PARP14 (poly (ADP-ribose) polymerase family, member 14) level was significantly increased in the peri-infarct zone of photothrombotic stroke (PT) mice. Genetic knockdown and pharmacological inhibition of PARP14 aggravated functional impairment and increased infarct volume in PT mice, while overexpression of PARP14 displayed the opposite effects. Furthermore, PARP14 was a...
Source: Autophagy - December 15, 2020 Category: Cytology Authors: Tang Y, Liu J, Wang Y, Yang L, Han B, Zhang Y, Bai Y, Shen L, Li M, Jiang T, Ye Q, Yu X, Huang R, Zhang Z, Xu Y, Yao H Tags: Autophagy Source Type: research
Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges
Abstract
Ischemic stroke is a focal cerebral insult that often leads to many adverse neurological complications severely affecting the quality of life. The prevalence of stroke is increasing throughout the world, while the efficacy of current pharmacological therapies remains unclear. As a neuroregenerative therapy, the implantation of human umbilical cord mesenchymal stem cells (hUC-MSCs) has shown great possibility to restore function after stroke. This review article provides an update role of hUC-MSCs implantation in the treatment of ischemic stroke. With the unique “immunosuppressive and immunoprivilege” ...
Source: Frontiers of Medicine - December 9, 2014 Category: Journals (General) Source Type: research
FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation
Autophagy. 2022 Sep 28:1-20. doi: 10.1080/15548627.2022.2116833. Online ahead of print.ABSTRACTProper termination of cell-death-induced neural inflammation is the premise of tissue repair in acute ischemic stroke (AIS). Macrophages scavenge cell corpses/debris and produce inflammatory mediators that orchestrate immune responses. Here, we report that FOXP3, the key immune-repressive transcription factor of Tregs, is conditionally expressed in macrophages in stroke lesion. FOXP3 ablation in macrophages results in detrimental stroke outcomes, emphasizing the beneficial role of FOXP3+ macrophages. FOXP3+ macrophages are distin...
Source: Autophagy - September 28, 2022 Category: Cytology Authors: Wei Cai Mengyan Hu Chunyi Li Ruizhen Wu Danli Lu Chichu Xie Wei Zhang Tiemei Li Shishi Shen Huipeng Huang Wei Qiu Quentin Liu Yan Lu Zhengqi Lu Source Type: research
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
CONCLUSIONS: Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting.
PMID: 24470059 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Hormone Therapy in Women After Heart Transplantation
Conclusions: HT is not associated with poor outcome or adverse effects in female heart transplant patients after age 35 years. However, a larger cohort of patients is necessary to confirm these observations.
Source: Transplantation Proceedings - November 1, 2013 Category: Transplant Surgery Authors: L.C. Kobashigawa, M. Hamilton, M. Rafiei, L. Stern, C.N. Bairey Merz Tags: Thoracic Transplantation Source Type: research
Neurological complications in renal transplant patients: A single-center experience
Conclusion We conclude that complications involving the neurological system occur in 10.5% of all transplant patients with 8% involving CNS and 7% involving the PNS. The high mortality rates associated with CNS complications warrant early diagnosis and aggressive treatment in renal transplant recipients.
Source: Indian Journal of Transplantation - November 24, 2015 Category: Transplant Surgery Source Type: research
RNase A in (Xeno)Transplantation
ConclusionsRNase A significantly improved graft survival. On the basis of these sweeping results, however, we suppose that RNase A could be an important adjuvant drug not only in allotransplantation but even in xenotransplantation.
References[1] Fischer S, Gerriets T, Wessels C, et al. Extracellular RNA mediates endothelial‐cell permeability via vascular endothelial growth factor. Blood 2007; 110(7): 2457–2465.[2] Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104(15): 6388–6393.[3] Fischer S, Grantzow T,...
Source: Xenotransplantation - April 19, 2014 Category: Transplant Surgery Authors: Eike Kleinert, Bruno Reichart, Tanja Mayr, Jan‐Michael Abicht, Paolo Brenner, Christian Hagl, Martin Langenmayer, Ruediger Wanke, Elisabeth Deindl, Sonja Guethoff Tags: Program and Abstracts Source Type: research
Medtech approvals: FDA releases August 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in August 2015:
Summary of PMA Originals & Supplements Approved
Originals: 2
Supplements: 70
Summary of PMA Originals Under Review
Total Under Review: 57
Total Active: 28
Total On Hold: 29
Summary of PMA Supplements Under Review
Total Under Review: 569
Total Active: 422
Total On Hold: 147
Summary of All PMA Submissions
Originals: 5
Supplements: 90
Summary of PMA Supplement PMA Approval/Denial Decision Times
Number of Approvals: 70
Number of Denials: 0
Average Days Fr Receipt to Decision (Total Time): 229.0
FDA Time: 130...
Source: Mass Device - October 23, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Pre-Market Approval (PMA) Regulatory/Compliance Source Type: news
MassDevice.com +5 | The top 5 medtech stories for November 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Final FDA rules clarify adverse event reporting for contract manufacturers
The FDA last week issued final guidance for medical device companies on the requirements for reporting adverse events that walked back much of the burde...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Heart Transplant Outcomes in Patients With Pretransplant Diabetes Mellitus.
CONCLUSIONS: Heart transplant recipients with pretransplant diabetes fared just as well as patients without pretransplant diabetes in 7 of the 8 outcomes examined, except for the number of days hospitalized during the first 3 years after heart transplant. This study provides clinically important new information on the greater hospitalization time and the reasons for hospitalization during the first 3 years after heart transplant in patients with pretransplant diabetes.
PMID: 29092871 [PubMed - in process]
Source: American Journal of Critical Care - November 1, 2017 Category: Nursing Authors: Jalowiec A, Grady KL, White-Williams C Tags: Am J Crit Care Source Type: research
